Linked Life Data

12376201

Source:http://linkedlifedata.com/resource/pubmed/id/12376201

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
15
pubmed:dateCreated
2002-10-11
pubmed:abstractText
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial is a randomised, double-blind, double-dummy trial, evaluating anastrozole alone or in combination with tamoxifen compared with tamoxifen alone, as a 5-year adjuvant treatment for postmenopausal patients with early breast cancer. The rapid rate of recruitment into this trial was a major achievement, as frequently encountered differences between projected and actual recruitment rates can threaten the successful completion of clinical trials. A questionnaire designed in order to highlight possible factors influencing the success of patient recruitment was completed by 62% of the ATAC trialists. This included 11 statements rated for their level of importance on a three-point scale. The top three motives for recruiting patients were: (1) the attractive scientific rationale of the trial (84%); (2) a design that was easy to explain to patients (79%); and (3) a pragmatic trial design in line with standard practice (76%). A new questionnaire will solicit opinion from the participating patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0959-8049
pubmed:author
pubmed:issnType
Print
pubmed:volume
38
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1984-6
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment.
pubmed:affiliation
The Portland Hospital, First Floor, 212-214 Great Portland Street, London W1W 5QN, UK. m.baum@ctc.ucl.ac.uk
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial